To view this email as a web page, click here

Today's Rundown

Featured Story

FDA puts Altimmune's intranasal COVID-19 vaccine trial on hold

The FDA has put a planned phase 1 clinical trial of Altimmune’s intranasal COVID-19 vaccine on clinical hold. Altimmune attributed the setback to the need for protocol modifications and additional chemistry, manufacturing and controls (CMC) data. 

read more

Top Stories

Ascendis files IND for sustained-release, anti-cancer TLR drug

Ascendis Pharma has filed to run a clinical trial of an intratumoral, sustained-release formulation of resiquimod. The TLR agonist has shown preclinical promise as a cancer therapy, but its clinical use has been held back by tolerance, poor solubility and adverse effects associated with systemic delivery.

read more

Nanoparticle drug delivery shows promise in brain injuries

A nanoparticle drug delivery system designed to shuttle molecules across the blood-brain barrier has shown promise in preclinical tests. The researchers used the system to transport siRNA across the intact blood-brain barriers of mice, pointing to its potential use in the treatment of traumatic brain injury.

read more

Tonix deal sets up use of intranasal drug in diabetes, obesity

Tonix Pharmaceuticals has struck a licensing deal to expand use of its intranasal potentiated oxytocin into cardiometabolic syndromes. The agreement gives Tonix exclusive rights to University of Geneva technology covering oxytocin-based treatments for insulin resistance, diabetes and obesity.  

read more

Becton Dickinson, ramping up syringe capacity, set to turn out 1B COVID-19 vaccine devices by year-end

Beckton Dickinson has taken orders for more than 1 billion pandemic needles and syringes, and that's just a piece of the company's COVID-19 battle plan. Next up, BD will overhaul its prefilled syringe capacity to keep the vaccine supply chain running as mass immunization campaigns ramp up.

read more

New drug approvals hit a high note in 2020 but face uncertainty in 2021

2020 didn't match 2018's record-breaking performance in the new drug approvals department, but it came pretty darn close.

read more

Resources

Webinar: Using SPOT™ & CHO-BC® During Cell Line Development for Titers up to 9 g/L

Innovative cell lines and early process development are critical to generate a high producing cell lines alongside a USP strategy to meet high quality standards.

Whitepaper: Success in Rare Diseases: Understanding the Rare Disease Ecosystem

Biopharma companies in rare diseases: How to maximize the odds of success by becoming a valued member of the unique “rare disease ecosystem.”

Infographic: 6 Ways Phenotypic Data Improves Decision-Making in Your Drug Development Program

Learn six ways metabolomics provides greater confidence, higher success rates and complements the work of your in-house teams for your drug development pipeline.

Whitepaper: The Future of Pharmacovigilance

Download the whitepaper to learn how your safety organization can implement automation technologies to enable process and cost efficiencies, improve resource allocation and ensure compliance and quality.

Whitepaper: Survey Reveals Demand for Clinical Trial Innovation in the Wake of COVID-19

The BBK Worldwide Study Voices 2020 survey gives voice to the healthcare consumer in the wake of COVID-19 and reveals important insights for clinical trial enrollment and engagement.

Infographic: Reducing Time to Clinic for Your Biomedical Applications

This infographic describes the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Whitepaper: Gene and Cell Therapy: Planning for Manufacturing Success Early

Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience.

Whitepaper: Companies Need An Effective Remote Workforce Cloud Strategy To Survive

A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Q&A: Planning Successful Launches

Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools.

eBook: CMC Considerations for Successful Early Drug Development

This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success.

Webinar: Phase Appropriate Expertise and Technologies to Accelerate Product Development to Commercialization

In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Executive Summary: Keys to a Successful Rapid Commercial Launch

Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

Events